Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
autologous bone marrow-derived mesenchymal stem cells (Royan Institute) (Royan Institute)
- Development stage
- Unknown
- Lead developer
- Royan Institute
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intraarticular
01
Overview
This investigational cell therapy, developed by the Royan Institute in Iran, consists of autologous, culture-expanded bone marrow-derived mesenchymal stem cells (BM-MSCs). Administered via intra-articular injection, the therapy is intended for the treatment of moderate to severe knee osteoarthritis. Its mechanism of action relies on the immunomodulatory properties of MSCs, which help control inflammation by acting on T lymphocytes, and the paracrine secretion of regenerative factors that promote the resurfacing of damaged articular cartilage. Clinical data from the RIMRO-TriaL suggests that the treatment is safe and effective in reducing pain and functional impairment in patients with knee osteoarthritis.
- Other names
- mesenchymal-Royan Institute-osteoarthritis (knee)BM-MSCsautologous bone marrow-derived mesenchymal stem cellsRoyan Institute BM-MSCs
Beyond the preview
Go deeper on autologous bone marrow-derived mesenchymal stem cells (Royan Institute) (Royan Institute).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on autologous bone marrow-derived mesenchymal stem cells (Royan Institute) (Royan Institute).